"Nigeria: Pediatricians Seek Routine Immunization for Hib"

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

                   

------------------------------------------------------------

 

July 3, 2002

 

INTERNATIONAL IMMUNIZATION NEWS

 

"Nigeria: Pediatricians Seek Routine Immunization for Hib" Africa News Service (www.allafrica.com) (07/02/02)

 

Nigerian government officials are being urged to include the Haemophilus influenzae type b (Hib) vaccine into the national immunization program.  Speaking last week at a Hib conference sponsored by the Pediatric Association of Nigeria (PAN) and the drugmaker GlaxoSmithKline, PAN president Kike Osinusi asserted that since Hib conjugate vaccines were introduced in the late 1980s and incorporated into national immunization programs in many developed and some developing nations, morbidity and mortality from the disease have dropped significantly.  Osinusi presented a paper, titled "The Burden of Hib Disease: A Case for Inclusion in the National Programme on Immunization," in which she stated that immunization is the best means of controlling the deadly disease.  According to Osinusi, "The vaccines that effectively control the rising incidences of mortality and morbidity from Hib disease are available, and can be provided by the GAVI, but government has to show commitment, and capability of handling and distributing it to those most in need of it."

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.